Cash, cash equivalents and short-term investments as of December 31, 2024, were $60.2 million. Monopar expects that its current funds will be sufficient to continue operations at least through December 31, 2026, in order to: assemble a regulatory package and file an NDA for ALXN1840; continue to conduct and conclude its first-in-human imaging and dosimetry clinical trial with MNPR-101-Zr; continue to conduct its first-in-human therapeutic clinical trial of MNPR-101-Lu; advance its preclinical MNPR-101-Ac program into the clinic; and invest in internal research and development projects to expand its radiopharma and rare disease pipeline.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Therapeutics reports Q4 EPS ($2.23) vs. (60c) last year
- Buy Rating for Monopar Therapeutics Inc. Driven by Strategic Acquisition and ALXN1840 Potential
- Monopar Therapeutics assumed with an Overweight at Piper Sandler
- Is MNPR a Buy, Before Earnings?
- Monopar Therapeutics Appoints Quan Vu as New CFO